Impact Biomedical, Inc. focuses on developing innovative health solutions inspired by nature, aiming to address unmet needs in human healthcare and wellness. The company has a diverse portfolio of patented technologies, including 3F™, Equivir, LineBacker, and Laetose. The 3F™ technology utilizes specialized botanical ingredients, such as terpenes, to create formulations that serve as insect repellents and antimicrobials. Equivir combines FDA Generally Recognized as Safe (GRAS) polyphenols with proven antiviral effects, while LineBacker enhances the potency and bioavailability of small molecule polyphenols, ensuring safety and efficacy. Laetose is designed to mitigate the inflammatory and metabolic responses associated with sugar, showcasing the company's commitment to developing natural alternatives to conventional medical treatments.

The company is strategically positioned to license its technologies to pharmaceutical firms and venture capitalists, with a focus on advancing medical treatments in areas such as neurology, inflammatory diseases, and vaccines. Impact Biomedical's research and licensing efforts extend to consumer wellness products, including sugar substitutes, insect repellents, immune supplements, and over-the-counter medicines. By leveraging its unique technology assets and partnerships, Impact Biomedical aims to create sustainable and effective health solutions that align with modern advancements in healthcare.

United States

Impact Biomedical, Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc.

Impact Biomedical, Inc.

Company Details